The multiple pharmacological actions of a unique compound are a prerequisite for classifying drugs as highly e‹cacious, because the multiple pharmacological actions oŠer the possibility of treating various symptoms of chronic diseases as described below. 1) Sustained hyperglycemia induces macrovascular and microvascular complications in type 2 diabetes mellitus. Antihyperglycemic medication and the control of postprandial hyperglycemia are essentially important for normalizing plasma glucose level. Gymnemic acid IV isolated from Gymnema sylvestre (Asclepiadaceae) leaves has antisweet, antihyperglycemic, glucose uptake inhibitory, and gut glycosidase inhibitory eŠects. Most of these pharmacological eŠects may synergistically contribute to alleviating type 2 diabetes-related symptoms. 2) Diabetic skeletal and vascular smooth muscles are hypersensitive to chemical transmitters, cytokines and autacoids. The sensitivity of neuromuscular synapses is enhanced in diabetes, which seems to be closely associated with neuropathy as one of the diabetic complications. b-Eudesmol found in Atractylodes lancea rhizome has a desensitizing channel blocking action to nicotinic acetylcholine receptors, anti-angiogenic action in vascular endothelium, and neuronal diŠerentiation actions. These multiple pharmacological actions are favorable for treating angiogenic diseases possibly including the complications of diabetes, namely, retinopathy and nephropathy, and cancer. 3) Nipradilol is clinically utilized as a topical antiglaucoma drug. The ocular hypotensive eŠects of this compound are brought about by its a 1 -and b-adrenergic receptor blocking actions, and nitric oxide (NO) releasing action. NO directly activates cyclooxygenases. All these pharmacologic eŠects are beneˆcial for treating glaucoma. The selectivity and speciˆcity of drug action are required for treating acute diseases, infections or for acting as useful reagents. The pleiotropic actions of natural compounds and their derivatives serve as important clues for developing new drugs for various chronic diseases.
INTRODUCTION
After serendipitous biologicalˆndings had been made, certain prototypic structures were further derivatized to obtain compounds with improved or e‹cacious novel pharmacologic eŠects. Selectivity and speciˆcity have been considered to be prerequisites for considering compounds as beneˆcial drugs such as antibiotics for acute infections or forˆnding useful reagents in research. However, it is not very important for clinicians to prescribe certain medicines for chronic diseases because these medicines often cause severe side eŠects due to their speciˆcity in vivo. There are many cases wherein natural products and synthetic compounds by themselves exert multiple pharmacological actions. These pharmacological multiactions become practical prerequisites for identifying highly e‹cacious drugs with multiple pharmacological actions for the simultaneous treatment of multifactorial symptoms of chronic diseases. In this study, an antihyperglycemic drug, an antiangiogenic drug, and an antiglaucoma drug having pleiotropic actions will be discussed as therapeutic compounds.
MULTIDIRECTIONAL ANTIHYPERGLYCEMIC ACTIONS OF GYMNEMIC ACID IV
Over the last few decades, there has been an exponential increase in the prevalence of type 2 diabetes worldwide, with estimates suggesting that 200 million people now suŠer from the condition. Type 2 diabetes mellitus is a chronic metabolic disorder caused by insulin deˆciency or insulin resistance. Sustained hyperglycemia induces macrovascular (mostly atherosclerosis) and microvascular complications (retinopathy, Inhibiting intestinal glucose absorption and hepatic glucose output, increasing glucose uptake in striated muscles, and stimulating insulin secretion unless patients suŠer from insulin resistance, are methods for preventing diabetes. From traditional Kampo medicines to herbs and foodstuŠs, we have also screened candidate crude drugs and constituent compounds with antihyperglycemic eŠects in type 2 diabetic model rodents, and in healthy human volunteers with improvement of oral glucose tolerance. The natural compounds investigated were categorized as follows. 1) Compounds that stimulate insulin secretion: non-saponin fraction of ginseng root (Panax spp., Araliaceae), 1, 2) fagomine, a N-containing sugar derived from mulberry leaves ( Morus spp., Moraceae.) [3] [4] [5] and gymnemic acid IV ( Fig. 1(A) ) derived from Gymnema sylvestre (Asclepiadaceae) leaves, 6) 2) Compounds that inhibit intestinal glucose absorption (glycosidase inhibition): gymnemic acid IV, 3) Compounds that increase glucose uptake in striated muscles: mulberry leaf extract, 7) 4) Compounds that inhibit the sweet taste (antisweet eŠect): gymnemic acid IV, 8) 5) Compounds with other mechanisms not associated with insulin release: pseudoproto-timosaponin-AIII derived from rhizomes of Anemarrhena asphodeloides (Liliaceae), 9) and green tea (Camellia sinensis, Theaceae), 10) and with unidentiˆed mechanisms: isofumulones from ‰ower cone with lupulin of hops (Humulus lupulus L., Moraceae). 11) Some of these natural products are contained in traditional medicines composed of various compounds, such as``byakkokaninjinto'' (composed of the rhizome of Anemarrhena asphodeloides, ginseng root, licorice root, rice grain, andˆbrosum gypsum). 12) The decisive selection and use of these natural compounds depend on the disease state of prediabetic or diabetic patients to prevent the aggravation of the disease.
Gymnemic acid IV mentioned above is a multidirectional ( Table 1) antihyperglycemic agent which has 1) antisweet taste, 8) 2) blood-glucose 
○：eŠective, -：no eŠect, vacant column：not tested.
(Reprinted from Sugihara et al., 2000, with permission from JANPR). 6) lowering ( Fig. 1(B) ), 6) 3) glucose uptake inhibitory, and 4) gut glycosidase inhibitory ( Table 1) actions. 7) Most of these pharmacological actions may beneˆ-cially contribute to alleviating type 2 diabetes-related symptoms. Thus, gymnemic acid IV may be used as a prophylactic against diabetes through its diŠerent mechanisms of action.
MULTIDIRECTIONAL ACTIONS OF b-EUDESMOL
Microangiopathy (retinopathy, nephropathy and neuropathy) develops as a consequence of sustained hyperglycemia. The skeletal and vascular smooth muscles are hypersensitive to chemical transmitters, cytokines and autacoids in diabetic state; this hypersensitivity is attributed to the up-regulation of their receptors caused by a deˆciency in the amounts of the endogenous mediators. Traditional medicines are frequently used to improve diabetic complications. We have clariˆed the mechanisms underlying the drug actions in neuromuscular synapses and blood vessels of diabetic rodents. The sensitivity of neuromuscular synapses is enhanced in the diabetic state, and the inhibition of neuromuscular synapses by suxamethonium, a depolarizing and desensitizing neuromuscular blocker, is enhanced in the disease state. Similarly, the neuromuscular blockade caused by a traditional prescription of a combination of crude drugs``keishikajutsubuto'', mainly consisting of peony root, licorice root, Atractylodes lancea rhizome and aconite root, is enhanced in the diabetic state. 13) b-Eudesmol, a sesquiterpenoid alcohol derived from A. lancea rhizomes, enhances the neuromuscular blocking action of suxamethonium 14) by inducing nicotinic acetylcholine receptor (nAChR) desensitization 15) and its neuromuscular blocking eŠect is exerted more in diabetic mice than in normal mice. 13 ) bEudesmol alone depresses nerve-evoked twitch tension, decreases the amplitude of acetylcholine potential, and reduces the amplitude and quantal size of endplate potential, but it does not alter quantal content, resting membrane potential and action potential. 16) This compound accelerates the slow decay of depolarization, and decreases both open time and opening frequency without aŠecting single-channel conductance, suggesting a mixed type nAChR-channel blocking eŠect ( Table 2 ) (open-channel blocking and closed-channel blocking eŠects). 17, 18) This blocking eŠect occurs at lower concentrations of b-eudesmol than those of bupivacaine, an open-channel blocker. The compound shortens the duration of nAChR activity-modulating noncontractile intracellular Ca 2＋ (RAMIC) 19) in isolated skeletal muscle endplates, and it enhances the suxamethonium-induced inhibition of contractile Ca 2＋ transients in isolated skeletal muscles of mice. 18) We previously reported that an extract of A. lancea rhizomes, containing the bioactive compound beudesmol, inhibits the angiogenesis of adjuvant-induced air pouch granuloma in mice, an in vivo model of chronic in‰ammation. 20) The degree of angiogenesis in vivo was determined in adjuvant-induced granuloma in mice by measuring carmine content. The intraperitoneal injection of b-eudesmol induced a marked reduction in angiogenesis than that of hydrocortisone ( Table 3) . 21) b-Eudesmol inhibits tube formation (angiogenesis) of endothelial cells in the rat aorta (unpublished data). The antiangiogenic eŠect of b-eudesmol is greater than that of hydrocortisone ( Fig. 2(A) ). The proliferation of porcine brain microvascular endothelial cells and human umbilical vein endothelial cells (HUVEC) is also inhibited by b-eudesmol. 21) It inhibits HUVEC migration stimulated by basicˆbroblast growth factor and tube The carmine content is an index of newly formed blood vessels in pouch granuloma. Data are means±S.E.M.n＝number of data. The extent of inhibition is expressed as a percentage of the carmine content in each control. a) p＜0.01 vs. control. formation of HUVEC in Matrigel. b-Eudesmol inhibits the angiogenesis in subcutaneously implanted Matrigel plugs in mice, the extent of which is much higher than that of thalidomide ( Fig. 2(B) ). 21) The blockade of extracellular signal-related kinase 1/2 by b-eudesmol may be the common mechanism for its antiangiogenic action. Therefore, b-eudesmol exhibits the following multiple pharmacological actions: 1) desensitization (channel blocking action) of nAChR, 2) antiangiogenic actions in the vascular endothelium, and 3) neuronal diŠerentiation induction (Fig. 2(C) ). 22 
BLOOD PRESSURE LOWERING EFFECT OF STEROIDAL VERATRUM ALKALOIDES WITHOUT VERATRIDINE-LIKE MECHANISMS
Crude alkaloids isolated from Veratrum (viride, V. grandi‰orum, V. oxysepalum and V. stamineum (Liliaceae) have been shown to continuously lower blood pressure markedly in wild dogs. 23) Crude alkaloids from V. nigrum var. ussuriense, and V. mackii, and their constituents, namely, germidine and germerine, lower blood pressure and increase pulse rate in conscious mice. 24) Veratridine, a steroidal alkaloid constituent derived from V. album, activates the Na ＋ channel by blocking its inactivation, followed by the prolongation of the opening of the channel and its action potential, and augments cardiac contractions. The alkaloid also alters the gating and permeability properties of Na ＋ current. 25) Germerine and germidine (Fig. 3(A) ) decrease blood pressure accompanied by positive chronotropy (Figs. 3(B) , (C)), whereas veratridine (Fig. 3(A) ) decreases blood pressure accompanied by negative chronotropy (Fig. 3(C) ). Therefore, germerine analogues are more favorable candidates as antihypertensive drugs than veratridine.
CENTRAL MUSCARINIC CARDIOTONIC ACTIONS OF ACONITINE
Processed aconite roots that contain small amounts of aconitine, which is regarded only as a neurotoxin by Western scientists, have continued to be clinically EŠects of nipradilol, timolol, bunazosin, and their combinations (nipradilol＋bunazosine, and timolol＋bunazosine) on ocular normotensive rabbits. For the combined treatment, nipradilol or timolol was instilled 5 min before bunazosin instillation. IOP was measured 60 min after drug instillation. As for the control, saline was used. b) Additive eŠects of nipradilol, timolol, and bunazosin on ocular normotensive rabbits 60 min after 5％ timolol instillation, under conditions saturated with adrenergic b-blocking activity. IOP was measured before 5％ timolol application (-60 min), and 0 min and 60 min after drug instillation. As for the control, saline was instilled. c) Additive eŠects of nipradilol and timolol on ocular normotensive rabbits 60 min after 0.1％ bunazosine instillation, under conditions saturated with a1-blocking activity. IOP was measured before 0.1％ bunazosine application (-60 min) and 0 min and 60 min after drug instillation. As for the control, saline was instilled. Data represent the decrease in IOP from the value at 0 min and are expressed as the mean±S.E.M. of six rabbits. (Dunnett's multiple range test;  p＜0.05,   p＜0.01 vs IOP decrease in saline control. 40) used in China and Japan for many years because of their therapeutic value. Their toxicities are minimized to a tolerable level during processing. Aconitine has a wide range of pharmacological actions at very low concentrations. Processed aconite roots have frequently been used in Kampo medicines to partially relieve muscle pain due to their neuromuscular blocking actions, 13, 26) and as cardiotonic and anti-in‰am-matory agents. 27) All of these actions may be due to the induction of the opening of voltage-sensitive Na ＋ channels in various cell types. 28) Aconitine increases spontaneous ACh release from the frontal cerebral cortex 29, 30) and from the motor nerves through the prolonged activation of Na ＋ channels (Figs. 4(A),   (B) ). 31) When administered peripherally, aconitine induces bradycardia (Fig. 4(C) ), probably through a pathway involving the anterior hypothalamus in conscious mice (Fig. 4(D) ). 32, 33) Aconitine is equipotent to hydrocortisone and indomethacin in inhibiting angiogenesis, 27) and it stimulates the response to interferon-g-activated expression of major histocompatibility complex class II antigen by macrophages in mice. 34) ANTIGLAUCOMA ACTIONS OF NIPRADILOL Nipradilol (3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-nitroxy-2H-1-benzopyran) is clinically utilized as a topical antiglaucoma drug. Initially, nipradilol was synthesized as an antihypertensive agent having b-adrenoceptor blocking actions, 35) and then as a nonselective a 1 blocking agent. [36] [37] [38] The ocular hypotensive eŠects of the compound are caused by increased ocular blood ‰ow due to its nonselective a 1 -blocking actions, b-adrenergic blocking actions, and nitric oxide (NO) production through its denitriˆcation (Figs. 5(A), (B), (C) ). 39, 40) Nipradilol has also been shown to dilate canine retinal artery and arteriole, 41) and substantially increase uveoscleral out‰ow. 42) The topical application of nipradilol suppresses the endothelin-1-induced contraction of the retinal artery, 43) and lowers intraocular pressure in ocular hypertensive rabbits. 44) All these eŠects are considered to contribute to the clinical antiglaucoma actions of nipradilol.
DISCUSSION
In this review, we have demonstrated the multiple pharmacological actions of gimnemic acid IV as an antihyperglycemic agent, b-eudesmol as an antiangiogenic agent, germerine as an antihypertensive agent, aconitine as an activator for the release of endogenous bioactive substances, and nipradilol as an antiglaucoma drug.
Salicin, found in many species of willow (Salix species; Salicaceae) inactivates cyclooxygenase-2, and is responsible for the analgesic and antipyretic eŠects of willow barks. Salicin also serves as the template for the synthesis of aspirin which is a more eŠective analogue. Aspirin, a traditional nonsteroidal anti-in‰am-matory drug, that inhibits both cyclooxygenase-1 and -2 is re-evaluated and classiˆed as a powerful drug having multiactions for the prophylactic treatments of cardiac infarction, angina pectoris, stroke, and dementia (Fig. 6) . Patients undergoing coronary angioplasty are given aspirin because it reduces thromboxane A 2 production and platelet clumping and hence, the possibility of myocardial infarction. 45) Aspirin also triggers the generation of lipoxin, which partially counteracts the adverse eŠects of prostaglandin suppression. 46) Its anti-in‰ammatory and antiplatelet eŠects may be due to its multiple pharmacological actions.
A single crude drug in traditional medicine frequently contains yin-yang components that have mutually opposing pharmacological activities beneˆ-cial for the targeted disease. The higher potency of the crude drug is brought about by the synergistic eŠect among its component compounds, even though the potency of each compound is weak when used alone. This is one reason why Kampo formulation is composed of several crude drugs. 47) However, a single pure compound by itself has multiple pharmacological actions similarly to a single crude drug. Their actions may likely be linked to common proteins in physiological or pathological circuits. Genome sciences, combined with bioinformatic tools, also allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable areas for intervention for future therapies, thereby increasing the number of treatment options. 48) If all multiple pharmacological actions are e‹ciently combined in one compound to cure chronic diseases exhibiting various symptoms without harmful side eŠects, this compound will be considered as a highly e‹cacious drug due to its pleiotropic actions.
CONCLUSION AND PERSPECTIVES
It is well recognized that the selectivity and speciˆc-ity of drug action are required for eŠectively treating acute diseases, infections or for acting as useful reagents. The nosological entities in lifestyle-related diseases can be classiˆed as multifactorial diseases. For chronic multifactorial diseases, the pleiotropic actions of gimnemic acid IV, b-eudesmol, nipradilol and aspirin may still continue to be eŠectively and therapeutically exploited in the future. The present lines of evidence suggest that pleiotropic actions are important in developing new drugs for chronic diseases presenting various symptoms.
